A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.

Trial Profile

A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2018

At a glance

  • Drugs Atesidorsen (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 24 May 2018 Results presented in an Antisense Therapeutics media release.
    • 24 May 2018 Reduction in serum insulin-like growth factor-I (sIGF-1) levels from baseline at week 14, according to an Antisense Therapeutics media release
    • 24 May 2018 According to an Antisense Therapeutics media release, the company announces that, the acceptance of publication of this trial data in journal of the European Journal of Endocrinology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top